These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20435447)

  • 21. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM; Naber D
    Schizophr Res; 2010 May; 118(1-3):176-82. PubMed ID: 20080036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attitude towards adherence in patients with schizophrenia at discharge.
    Schennach-Wolff R; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
    J Psychiatr Res; 2009 Dec; 43(16):1294-301. PubMed ID: 19505697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.
    Schennach-Wolff R; Meyer S; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
    J Psychiatr Res; 2011 Dec; 45(12):1639-47. PubMed ID: 21862035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status.
    Putzhammer A; Perfahl M; Pfeiff L; Hajak G
    Pharmacopsychiatry; 2005 May; 38(3):132-8. PubMed ID: 15902585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of depressive symptoms on subjective well-being: the importance of patient-reported outcomes in schizophrenia.
    Mauriño J; Sanjúan J; Haro JM; Díez T; Ballesteros J
    Patient Prefer Adherence; 2011; 5():471-4. PubMed ID: 22003284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subjective well-being in schizophrenia: a randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER).
    Naber D; Peuskens J; Schwarzmann N; Goltz M; Krüger H; Lambert M; Haro JM
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1257-69. PubMed ID: 23953270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of symptom remission in schizophrenia during inpatient treatment.
    Jäger M; Riedel M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Bottlender R; Strauss A; Möller HJ
    World J Biol Psychiatry; 2009; 10(4 Pt 2):426-34. PubMed ID: 17853260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs.
    Naber D; Moritz S; Lambert M; Pajonk FG; Holzbach R; Mass R; Andresen B
    Schizophr Res; 2001 May; 50(1-2):79-88. PubMed ID: 11378316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone.
    Westheide J; Cvetanovska G; Albrecht C; Bliesener N; Cooper-Mahkorn D; Creutz C; Hornung WP; Klingmüller D; Lemke MR; Maier W; Schubert M; Sträter B; Kühn KU
    J Sex Med; 2008 Dec; 5(12):2816-26. PubMed ID: 18466271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sample.
    Haring L; Mõttus R; Jaanson P; Pilli R; Mägi K; Maron E
    Ann Gen Psychiatry; 2013 Sep; 12(1):28. PubMed ID: 24025191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment.
    Hunter R; Barry S
    Eur Psychiatry; 2012 Aug; 27(6):432-6. PubMed ID: 21602034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intercultural differences in factor structure of the SWN-20 in patients with schizophrenia.
    Hwang SS; Kim EY; Kim SH; Kim YS; Ahn YM
    Compr Psychiatry; 2013 Oct; 54(7):970-3. PubMed ID: 23763873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
    Naber D
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.
    Naber D; Riedel M; Klimke A; Vorbach EU; Lambert M; Kühn KU; Bender S; Bandelow B; Lemmer W; Moritz S; Dittmann RW
    Acta Psychiatr Scand; 2005 Feb; 111(2):106-15. PubMed ID: 15667429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subjective effects of antipsychotic drugs and their relevance for compliance and remission.
    Naber D
    Epidemiol Psichiatr Soc; 2008; 17(3):174-6. PubMed ID: 18924553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.
    Wehmeier PM; Kluge M; Schacht A; Helsberg K; Schreiber W; Schimmelmann BG; Lambert M
    J Psychiatr Res; 2008 Jul; 42(8):676-83. PubMed ID: 17720192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale.
    de Haan L; Weisfelt M; Dingemans PM; Linszen DH; Wouters L
    Psychopharmacology (Berl); 2002 Jun; 162(1):24-8. PubMed ID: 12107613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales.
    Wolters HA; Knegtering H; van den Bosch RJ; Wiersma D
    Schizophr Res; 2009 Jul; 112(1-3):114-8. PubMed ID: 19395241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The concurrent and predictive validity of symptomatic remission criteria in first-episode schizophrenia.
    Chang WC; Chan TC; Chen ES; Hui CL; Wong GH; Chan SK; Lee EH; Chen EY
    Schizophr Res; 2013 Jan; 143(1):107-15. PubMed ID: 23151398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between subjective well-being and depressive symptoms in treatment-resistant schizophrenia before and after treatment with clozapine.
    Kim JH; Lee J; Kim YB; Han AY
    Compr Psychiatry; 2014 Apr; 55(3):708-13. PubMed ID: 24332387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.